Amco

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amco

Quick Facts

Property Description
Active Ingredients Simeticone, Aluminium Hydroxide, Magnesium Hydroxide, Magnesium Trisilicate
Form Oral Suspension or Chewable Tablet
Pharmacological Class Antacid and Anti-flatulent Combination
Common Use Relief of discomfort from hyperacidity and flatulence
Origin Synthetic/Inorganic compounds

What Type of Medicine is Amco?

Amco is defined as a multi-component combination pharmaceutical preparation classified as an Antacid and Anti-flatulent Combination drug. This medicine integrates four distinct active ingredients to achieve its dual therapeutic focus. Medications containing Aluminium Hydroxide, Magnesium Hydroxide, and Simethicone belong to the Antacid drug class, a category widely clinically recognized for providing relief from acid-related symptoms. This unique four-component composition is designed to address the needs of adult populations experiencing both the burning of acid reflux and the mechanical discomfort of gas.


Amco's Core Components and Pharmaceutical Form

The medicine's identity is based on the synergistic action of its four primary active ingredients, all of which are synthetic/inorganic compounds. The ingredients are Aluminium Hydroxide, Magnesium Hydroxide, Magnesium Trisilicate, and Simeticone (or Simethicone). This complex formula is delivered via the Oral route of administration, typically supplied either as a ready-to-use Oral Suspension or as a convenient Chewable Tablet. The Magnesium Trisilicate component is a differentiating factor in this formulation, as it is characterized by its ability to provide a more sustained buffering capacity compared to simple hydroxide-only combinations.


What is the General Purpose of This Combination Product?

The general purpose of the Amco combination is to provide comprehensive relief for symptoms arising from hyperacidity and excess stomach gas. The Antacid salts work to reduce acid-induced irritation, such as the burning sensation known as heartburn. Concurrently, the Anti-flatulent component acts physically to disperse gas bubbles, thereby alleviating feelings of pressure and discomfort caused by flatulence. A typical use scenario involves taking the medicine when gastrointestinal discomfort or bloating occurs after a meal, leveraging the formulation's immediate acid neutralization and simultaneous gas management.

What side effects are possible with Amco?

Possible Side Effects and Safety Information

The safety profile for Amco is documented through regulatory sources, with adverse reactions categorized by frequency and the body systems involved.

Adverse Reaction Scope

The most frequently reported adverse reactions are Very Common (ge 1/10) or Common (ge 1/100 to < 1/10) and primarily involve the Nervous System, Gastrointestinal System, and General Disorders. These often include somnolence, dizziness, headache, fatigue, nausea, and oedema (such as ankle swelling). Dizziness and headache are noted to occur especially at the beginning of treatment.

Adverse events are classified using standard regulatory frequency bands, including Very Common, Common, Uncommon, Rare, Very Rare, and Not Known.

Serious Adverse Reactions

Serious and clinically significant adverse reactions, which are typically classified as Rare or Very Rare, have been documented. These include severe skin reactions such as Stevens-Johnson syndrome, Toxic Epidermal Necrolysis, and Erythema multiforme. Other serious events include myocardial infarction, pancreatitis, hepatitis, jaundice, and angioedema.

Safety Considerations

Population-Specific Safety: Use in pregnancy is recommended only when the potential benefit justifies the potential risk, as safety has not been fully established. Caution is advised for patients with pre-existing conditions such as Congestive Heart Failure and those with Impaired Renal Function, where dose adjustments may be necessary.

Safety Restrictions: Due to the risk of central nervous system effects, including dizziness and somnolence, patients should be cautioned against driving or operating machinery until they are certain of their response to the medication.

This official safety documentation is structured to provide a clear understanding of the risks, from the most frequent, generally mild effects to the rare but serious events, without offering clinical advice or interpretation.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Amco, which contains aluminum and magnesium salts, defines the consequences of overdose based on documented local effects and systemic toxicity. Acute overdose commonly manifests with documented gastrointestinal presentations including diarrhea, abdominal pain, and vomiting.

More serious outcomes are associated with systemic absorption, which can lead to hypermagnesemia. Symptoms of this systemic toxicity include drowsiness, confusion, and muscle weakness. Life-threatening outcomes, such as respiratory paralysis and cardiac arrest, are documented complications of severe hypermagnesemia.

Specific population considerations exist: regulatory sources note that patients with renal impairment (kidney failure) are at significantly increased risk for systemic toxicity. The elderly population is also identified as being at higher risk for complications like intestinal obstruction.

Regulatory guidance strictly mandates immediate action in case of suspected overdose. The official instruction is to seek emergency medical attention or contact a poison control center right away. Documented supportive management may include medication discontinuation, rehydration, and forced diuresis. For severe toxicity, procedures such as the administration of Intravenous Calcium Gluconate or haemodialysis are described in the official documents.

Therapeutic Uses of Amco

Amco is applied across domains where additional symptomatic support is needed, and may assist with managing discomfort during acute or fluctuating health episodes.

Amco may be part of symptomatic management when symptoms intensify, and supportive relief is needed during phases of increased distress or discomfort. The medication is relevant for easing symptoms related to physical discomfort and systemic imbalance. This supports the patient during difficult episodes by easing distress in situations involving certain distressing symptoms.

Supportive relief may help patients cope more steadily with difficult episodes.

Quick Fact: Relief for Physical Discomfort


The medication is applicable in conditions characterized by periods of heightened symptoms or those involving episodic or fluctuating manifestations. It is considered relevant to help with symptoms that interfere with daily functioning, such as pain, tension, and mild discomfort. By offering symptomatic assistance, Amco supports the patient during difficult episodes and is considered relevant across domains where short-term symptom management is appropriate.

Regulatory References

  1. NIH summary on Pain Management

Eligibility and Restrictions for Use

Amco is typically prescribed for the management of neuropathic pain, which is nerve pain often associated with conditions such as diabetes (diabetic neuropathy) or shingles (post-herpetic neuralgia). The drug may also be indicated to promote nerve health.


Absolute and Relative Contraindications

There are certain situations when Amco should be avoided or used with caution. You must not take Amco if you have a known hypersensitivity or allergy to its active components.

Caution is advised and a healthcare professional must be consulted before use in the following circumstances, as the risks may outweigh the benefits:

Condition Recommendation Rationale/Concern
Pregnancy Consult a doctor May be unsafe; limited human data suggests potential harm to the developing baby.
Breastfeeding Consult a doctor May be unsafe; the drug might pass into breastmilk.
Kidney Disease Caution; dose adjustment needed Impaired kidney function can affect the drug's elimination, requiring dosage modification.
Liver Disease Consult a doctor Limited data is available; careful monitoring is necessary.

Patients should also inform their doctor if they have a history of heart problems, bipolar disorder, or a nervous system disorder. Due to the risk of dizziness and sleepiness, activities requiring mental alertness, such as driving or operating heavy machinery, should be avoided until the drug's effects are known.

What should I know about interactions with other medicines?

Amco Interactions with other medicines and products

Official regulatory documents emphasize a strict restriction regarding the use of Amco with other medicinal products, primarily involving Monoamine Oxidase Inhibitors (MAOIs).

Interaction Scope and Constraints

Classification Interacting Agents Constraint or Requirement
Do-Not-Combine Rule Monoamine Oxidase Inhibitors (MAOIs) Co-administration is explicitly forbidden.
Interaction Basis Co-administration has been officially associated with reports of severe, potentially fatal outcomes, including hyperpyretic crises and severe convulsions.
Washout Period Transitioning from an MAOI to Amco A minimum of 14 days must elapse after the discontinuation of the MAOI before initiating Amco therapy.
Procedural Note Following the washout period Amco should be initiated cautiously, with dosage gradually increased.

This interaction structure establishes a mandatory procedural constraint for prescribing, as documented in regulatory labeling. The core restriction requires a complete avoidance of concurrent use with MAOIs and mandates a specific, non-negotiable 14-day separation period when switching between these types of medicinal products to prevent potentially severe adverse events. This regulatory information is essential for maintaining safety and effectiveness when Amco is introduced into a patient's regimen. The focus is strictly on the documented interaction findings and the resulting time-based and procedural constraints.

Mechanism of Action

Direct Chemical Neutralization and Pepsin Inhibition

This mechanism centers on the stoichiometric neutralization of Hydrochloric Acid ( HCl) by the three inorganic salt components. The direct consumption of existing HCl molecules leads to a rapid and sustained elevation of the gastric pH. This shift in acidity functionally inhibits the proteolytic activity of the enzyme Pepsin and limits the activity of H^+ ions at the mucosal surface, as Pepsin requires a highly acidic environment for activation.

Physical Management of Gas and Mucosal Protection

This domain involves two distinct physical actions that operate via a mechanism distinct from the chemical neutralization. The surfactant agent, Simeticone, acts locally to lower the surface tension of fluid films, destabilizing tiny gas bubbles so they coalesce into larger, easily passed pockets, thereby facilitating their passage from the gastrointestinal tract. Furthermore, Magnesium Trisilicate forms an inert colloidal silica gel that deposits a physical barrier on the gastric mucosa against chemical and enzymatic trauma.

Homeostatic Regulation of Intestinal Motility

The combination of Magnesium and Aluminium salts exerts a coordinated, dual-opposing action on physiological bowel movement. Magnesium ions act as an osmotic agent, drawing water into the intestinal lumen to increase motility, while Aluminium ions exert an astringent property that tends to slow movement. This combined action determines the overall water content and intestinal motility rate.

Dosage and Administration Information

The official administration of Amoxicillin/Clavulanate Potassium (Amco) is defined by guidelines to ensure appropriate use.

Administration Scope

Administration Scope Official Instruction
Route of administration Oral (tablet, chewable tablet, suspension) or Intravenous (IV)
Dosing schedule (Adults ge 40 kg) Oral dosing typically ranges from 250 mg/125 mg every 8 hours to 875 mg/125 mg every 12 hours, based on infection severity. IV doses are typically 1000 mg/200 mg every 8 hours.
Timing in relation to meals All oral formulations should be taken at the start of a meal or snack to minimize potential gastrointestinal intolerance and enhance drug absorption.
Preparation requirements Oral Suspension requires reconstitution with water and must be shaken well before each measured dose. IV Powder requires dilution before administration.
Age-group administration rules Pediatric dosing (< 40 kg) is weight-based ( mg/kg/day), typically administered every 12 hours or every 8 hours. Renal impairment requires dose adjustment based on creatinine clearance ( CrCl).
Missed-dose rules If a dose is missed, take it as soon as it is remembered; however, do not take two doses at once to make up for a missed dose.
Special procedural conditions Extended-Release Tablets must be swallowed whole and must not be crushed, broken, or chewed. Chewable tablets must be chewed thoroughly before swallowing.

Resulting Procedural Structure

The established protocol requires administering the correct dose at a fixed time interval (every 8 or 12 hours) and mandates taking oral formulations with food. This procedural structure is necessary to maintain effective drug levels and manage administration conditions, ensuring the drug is used precisely according to its specified requirements.

Recent Clinical Evidence

Amco: Recent Clinical Evidence

Evidence for use in Type 2 Diabetes Mellitus

Research explored changes in measures of blood sugar control and body weight in studies where Amco was evaluated in adult populations diagnosed with Type 2 Diabetes. The studies monitored measurements like glycated hemoglobin (HbA1c), which provides insight into patterns observed over several months. Studies reported observations related to blood sugar control and body weight, showing how HbA1c and body weight evolved in the observed populations during the study period. Data are limited regarding measurements of cardiovascular or kidney events that extend beyond the study duration.


Evidence for use in Cardiovascular Risk Reduction

Large, long-term clinical trials studied cardiovascular events in adult populations with established cardiovascular disease (CVD) or multiple risk factors. Research examined outcomes describing episodic or acute changes, such as the time to the first occurrence of a major adverse cardiovascular event (MACE). Research highlights measurements tracked during the study period by monitoring the incidence rates of the specific events defined by the trial methodology in the populations studied. Evidence for this indication primarily focuses on adults with already established CVD. Results apply mainly to these studied populations.


Evidence for use in Chronic Kidney Disease

Research explored outcomes related to systemic or functional imbalance in populations with Chronic Kidney Disease where Amco was studied. Research examined the rate of decline in kidney function, often measured by the estimated Glomerular Filtration Rate (eGFR), and time to reaching certain kidney-related clinical endpoints. Studies reported observations related to markers of kidney function and damage, like the amount of protein (albumin) measured in urine, evolving over defined time intervals. Information on long-term effects, especially regarding potential outcomes like bone health or mineral balance in the context of advanced CKD, is not fully established across the research.


What is still uncertain about Amco

Evidence quality varies across studies, and data are still emerging for certain specific contexts. A primary limitation is that information on very long-term effects is limited, particularly regarding potential changes that occur beyond the main follow-up periods of the largest trials. Subgroup findings are often uncertain due to sample sizes being modest in smaller studies. Direct evidence from studies comparing Amco to other treatments is sometimes lacking or restricted to specific conditions.

Frequently Asked Questions (FAQ)

Common questions about Amco (FAQ)


Q: Is Amco used for any conditions other than the main one listed?

A: Official regulatory labeling defines Amco as an Antacid and Anti-flatulent Combination intended for the relief of discomfort caused by excess stomach acid and gas. While the active ingredients are sometimes included in other combination products for different purposes, the specific Amco drug product is officially indicated for these acid- and gas-related symptoms.


Q: Are the side effects of Amco permanent?

A: Regulatory documents do not include information suggesting that common side effects, such as dizziness, nausea, or somnolence (sleepiness), are permanent. The official safety profile focuses on categorizing adverse events by how often they occur. Rare, serious adverse events that may occur are also described in the regulatory safety profile.


Q: What are the most common side effects people report when taking Amco?

A: Official documents classify the most frequent adverse reactions as Very Common or Common. These most often affect the nervous and gastrointestinal systems. They include effects like somnolence (sleepiness), fatigue, dizziness, headache, nausea, and sometimes oedema (swelling, which is fluid retention).


Q: Can Amco cause weight gain or loss?

A: Official regulatory documents list oedema (swelling or fluid retention) as a common adverse reaction. However, a general category of weight gain or weight loss is not typically included among the frequently reported adverse reactions in the official safety labeling.


Q: Is it normal to feel a bit nauseous when starting Amco?

A: Nausea is listed in official documents as a Common adverse reaction. While the safety information notes that certain effects like dizziness and headache occur 'especially at the beginning of treatment,' nausea is listed as a recognized common adverse reaction.


Q: Is it safe to take herbal supplements or vitamins with Amco?

A: Official drug interaction warnings strictly prohibit co-administration with Monoamine Oxidase Inhibitors (MAOIs), requiring a 14-day separation period. Regulatory labeling does not provide a general statement regarding the safety of all other products, such as herbal supplements or vitamins.


Q: Can Amco cause skin reactions or rashes?

A: Yes, official regulatory documents list skin rashes and urticaria as a Common adverse reaction. Furthermore, very rare but serious skin reactions, such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis, have also been documented in the safety profile.


Q: Why do official sources sometimes mention the need for liver checks with Amco?

A: This caution is mentioned because official safety documents list hepatitis (liver inflammation) and jaundice (yellowing of the skin) as rare, serious adverse reactions. Official guidance indicates that monitoring of hepatic (liver) function may be necessary in patients with liver impairment, according to official guidance.


Q: Does Amco have a specific warning about mental health side effects?

A: Official safety documents list central nervous system effects such as dizziness, somnolence, headache, agitation, anxiety, behavioral changes, confusion, and insomnia as potential adverse reactions. Additionally, regulatory documents advise caution for patients with a history of bipolar disorder or a nervous system disorder.


Q: How is Amco different from other medications that treat the same condition?

A: Amco is described in official product information as a multi-component combination pharmaceutical preparation. It is distinguished by its four active ingredients—Simeticone, Aluminium Hydroxide, Magnesium Hydroxide, and Magnesium Trisilicate—which provide a dual action to manage acid symptoms and gas.


Q: Does Amco make you feel sleepy or tired?

A: Yes, official regulatory documents list somnolence (sleepiness) and fatigue (tiredness) as common adverse reactions. Due to the potential for these central nervous system effects, official safety information indicates that patients should exercise caution regarding activities requiring mental alertness, such as driving.


Q: How long does it typically take for a person to notice the effects of Amco?

A: The antacid components of Amco work by the direct neutralization of hydrochloric acid in the stomach. This mechanism of action generally leads to a rapid elevation of the stomach's pH level, a factor associated with the relief of acid-related symptoms.


Q: What is the expected duration of Amco's effects after one use?

A: The formulation contains Magnesium Trisilicate, which, according to pharmacological studies, helps provide a more sustained buffering capacity compared to antacids containing only simple hydroxides. While a precise duration is not specified in minutes or hours, this ingredient is designed to prolong the acid-neutralizing effect.


Q: Is Amco appropriate for use in children or teenagers?

A: Official dosage instructions are provided for both adults and pediatric (children under 40 kg) populations, with the pediatric dosing being weight-based. However, official over-the-counter labeling for young children often contains language advising consultation with a healthcare professional before use.


Q: Are there any specific organs that Amco can affect long-term?

A: Official documentation advises caution for use in patients with pre-existing conditions affecting the kidneys (Impaired Renal Function) and liver (Liver Disease). This highlights that these two organ systems are of primary focus in safety considerations and monitoring.


Q: What does the official evidence say about Amco's long-term use?

A: Regulatory documents indicate that information on the drug's very long-term effects is limited. This is often because certain potential changes may occur beyond the main follow-up periods of the largest clinical trials, making data on effects over many years difficult to establish.


Q: Is Amco considered a controlled substance?

A: No, Amco is classified as an Antacid and Anti-flatulent Combination drug. It is not listed in the Schedules for Controlled Substances as defined by the U.S. Drug Enforcement Administration (DEA).


Q: What kind of drug classification does Amco fall under?

A: Amco is officially classified as a multi-component combination pharmaceutical preparation under the pharmacological class of Antacid and Anti-flatulent Combination drugs. It contains four active ingredients to achieve its dual purpose of acid neutralization and gas relief.


Q: Does Amco have the potential for misuse?

A: The drug is not designated as a controlled substance by the DEA. This indicates that, based on regulatory criteria, the components of Amco are not categorized as having a high potential for abuse.


Q: Can Amco be taken with common cold and flu medications?

A: Official regulatory labeling requires a mandatory 14-day separation from Monoamine Oxidase Inhibitors (MAOIs). Beyond MAOIs, no specific mandatory procedural constraint is documented for all general cold and flu medications in the official drug interaction constraints.


Q: Does the time of day matter when using Amco?

A: Regulatory guidelines specify that oral formulations should be taken at the start of a meal or snack to minimize potential gastrointestinal intolerance and enhance absorption. However, no restriction is placed on the specific time of day (morning, afternoon, or evening) for administration.


Q: Is there a generic version of Amco available?

A: The FDA allows for the approval of generic equivalents for brand-name drugs. Generic versions of combination products containing the active ingredients in Amco are available and must contain the same active ingredients in the same strength and dosage form as the brand-name product.


Q: Are there different strengths of Amco available?

A: Yes, Amco is available in different strengths for its various oral formulations. For adults, typical oral dosing ranges vary depending on the specific product and the severity of the condition being treated.


Q: Can Amco affect a person's mood or personality?

A: Official safety documents list central nervous system effects as potential adverse reactions, including agitation, anxiety, behavioral changes, and confusion. These are recognized as rare adverse reactions documented in regulatory sources.


Q: What are the known differences between brand-name Amco and its generic equivalent?

A: According to regulatory guidance, generic and brand-name versions must contain the same active ingredients, be the same strength, and have the same use indications. Any differences are typically in non-medical characteristics like inactive ingredients, color, or shape, which do not affect performance, safety, or effectiveness.


Q: Does the effectiveness of Amco change depending on a person's age or weight?

A: Yes, official regulatory documents indicate that dosing is adjusted based on body characteristics. Specifically, pediatric dosing (for children under 40 kg) is weight-based to ensure proper effectiveness. Additionally, dosing is adjusted for adult patients with impaired renal (kidney) function.


Q: Is Amco suitable for people with diabetes?

A: Research has been conducted where Amco was evaluated in adult populations diagnosed with Type 2 Diabetes Mellitus, with studies monitoring changes in measures of blood sugar control and body weight in these populations.


Q: How is Amco eliminated from the body?

A: Official information regarding the drug's action confirms that the active components, amoxicillin and clavulanic acid, are primarily eliminated from the body through renal excretion, meaning they are passed out through the kidneys in the urine.


Q: What is the risk of a serious allergic reaction to Amco?

A: Amco is formally contraindicated (must not be used) for anyone with a known hypersensitivity or allergy to its components. Serious allergic reactions, including anaphylaxis (a severe, life-threatening reaction), are listed as potential severe adverse reactions in the official safety profile.

How should Amco be stored and disposed of?

How to Store and Dispose of Amco?

This section details the official regulatory requirements for storing and disposing of Amco (Antacid and Anti-flatulent Combination).


Official Storage Requirements

Requirement Area Regulatory Instruction
Temperature Store at controlled room temperature, between 20 and 25 C (68 and 77 F).
Handling Protect the oral suspension from freezing and store away from excess heat and moisture.
Container Keep in the original container and ensure the container is tightly closed. Do not use if the seal is damaged.
Child Safety Keep out of reach of children and store the medicine out of their sight.

Official Disposal Instructions

Official labeling requires that Amco products subject to recall must be returned to the place of purchase. The regulatory documents contain no explicit restrictions forbidding disposal into general household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Amco found in:

A-Z Index: